In 2001, after a long delay, the U.S. Food and Drug Administration rejected a cancer pill being developed by Bristol-Myers Squibb called UFT, starting years of bad luck for the New York-based drug maker. There’s only one problem: new data presented here yesterday shows UFT works, and some doctors say it probably should have been approved.
